Search Press releases Keywords From To 20 Nov 2020 Disposals of own shares Read More 17 Nov 2020 UCB’s VIMPAT[®] (lacosamide) CV now approved by FDA in U.S. for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy Read More 12 Nov 2020 UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms Read More 10 Nov 2020 Disposals of own shares Read More 6 Nov 2020 UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020 Read More 31 Oct 2020 Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira[®] in Moderate-to-Severe Psoriasis Patients Read More Pagination First page Previous page Previous … Page 47 Page 48 Page 49 Page 50 Current page 51 Page 52 Page 53 Page 54 Page 55 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
